An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT

BACKGROUND: Bendamustine is a bifunctional alkylating agent with unique properties that distinguish it from other agents in its class. Bendamustine is used as monotherapy or in combination with other agents to treat patients with non-Hodgkin lymphoma (nhl) and chronic lymphocytic leukemia (cll). MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Oncol
Main Authors: Kouroukis, C.T., Crump, M., MacDonald, D., Larouche, J.F., Stewart, D.A., Johnston, J., Sauvageau, S., Beausoleil, E., Sage, P., Dubois, S.G., Christofides, A., Di Clemente, S., Sehn, L.
Formato: Artigo
Idioma:Inglês
Publicado em: Multimed Inc. 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4530811/
https://ncbi.nlm.nih.gov/pubmed/26300664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2431
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados